Combination therapy for older adults with double-expressor lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) for older adults newly diagnosed with a certain type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this combination is safe and effective for people who may not be able to handle standard, more intense chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 or older, or you are between 60 and 69 and considered frail after a health check.
- You have been diagnosed with a specific type of large B-cell lymphoma (DLBCL) that has two proteins called MYC and BCL2 (called 'double-expressor').
- You have at least one tumor that can be measured or seen on scans.
- You have not had any prior treatment for this lymphoma.
- Your organs and bone marrow are working well enough to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Hear when a new Double Expressor DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.